Molecular Weight:   | 285.14 |
Volume:   | 298.468 |
LogP:   | 2.841 |
LogD:   | 3.446 |
LogS:   | -4.324 |
# Rotatable Bonds:   | 4 |
TPSA:   | 38.77 |
# H-Bond Aceptor:   | 4 |
# H-Bond Donor:   | 0 |
# Rings:   | 3 |
# Heavy Atoms:   | 4 |
QED Drug-Likeness Score:   | 0.633 |
Synthetic Accessibility Score:   | 2.344 |
Fsp3:   | 0.353 |
Lipinski Rule-of-5:   | Accepted |
Pfizer Rule:   | Accepted |
GSK Rule:   | Accepted |
BMS Rule:   | 0 |
Golden Triangle Rule:   | Accepted |
Chelating Alert:   | 0 |
PAINS Alert:   | 0 |
Caco-2 Permeability:   | -4.839 |
MDCK Permeability:   | 3.133480640826747e-05 |
Pgp-inhibitor:   | 0.993 |
Pgp-substrate:   | 0.009 |
Human Intestinal Absorption (HIA):   | 0.003 |
20% Bioavailability (F20%):   | 0.2 |
30% Bioavailability (F30%):   | 0.007 |
Blood-Brain-Barrier Penetration (BBB):   | 0.715 |
Plasma Protein Binding (PPB):   | 95.11874389648438% |
Volume Distribution (VD):   | 0.435 |
Pgp-substrate:   | 4.618494987487793% |
CYP1A2-inhibitor:   | 0.985 |
CYP1A2-substrate:   | 0.241 |
CYP2C19-inhibitor:   | 0.94 |
CYP2C19-substrate:   | 0.195 |
CYP2C9-inhibitor:   | 0.536 |
CYP2C9-substrate:   | 0.949 |
CYP2D6-inhibitor:   | 0.923 |
CYP2D6-substrate:   | 0.912 |
CYP3A4-inhibitor:   | 0.936 |
CYP3A4-substrate:   | 0.193 |
Clearance (CL):   | 10.777 |
Half-life (T1/2):   | 0.313 |
hERG Blockers:   | 0.856 |
Human Hepatotoxicity (H-HT):   | 0.121 |
Drug-inuced Liver Injury (DILI):   | 0.602 |
AMES Toxicity:   | 0.008 |
Rat Oral Acute Toxicity:   | 0.012 |
Maximum Recommended Daily Dose:   | 0.1 |
Skin Sensitization:   | 0.84 |
Carcinogencity:   | 0.853 |
Eye Corrosion:   | 0.068 |
Eye Irritation:   | 0.552 |
Respiratory Toxicity:   | 0.935 |
Natural Product ID:   | NPC136330 |
Common Name*:   | Piperine |
IUPAC Name:   | (2E,4E)-5-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylpenta-2,4-dien-1-one |
Synonyms:   | Piperine |
Standard InCHIKey:   | MXXWOMGUGJBKIW-YPCIICBESA-N |
Standard InCHI:   | InChI=1S/C17H19NO3/c19-17(18-10-4-1-5-11-18)7-3-2-6-14-8-9-15-16(12-14)21-13-20-15/h2-3,6-9,12H,1,4-5,10-11,13H2/b6-2+,7-3+ |
SMILES:   | O=C(N1CCCCC1)/C=C/C=C/c1ccc2c(c1)OCO2 |
Synthetic Gene Cluster:   | n.a. |
ChEMBL Identifier:   | CHEMBL43185 |
PubChem CID:   |
638024 |
Chemical Classification**:   |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPO28928 | NPC136330 | Raw | Fruit | 5350 | 1700 | 9000 | mg/100g | Database [DUKE] |
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 23.0 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 46.0 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 68.0 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Activity | = | 72.4 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Activity | = | 76.1 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Activity | = | 84.3 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Activity | = | 40.6 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Activity | = | 36.5 | % | PMID[459783] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Activity | = | 29.2 | % | PMID[459783] |
NPT1460 | Cell Line | L929 | Mus musculus | Activity | = | 64.0 | % | PMID[459783] |
NPT1460 | Cell Line | L929 | Mus musculus | Activity | = | 66.2 | % | PMID[459783] |
NPT1460 | Cell Line | L929 | Mus musculus | Activity | = | 92.2 | % | PMID[459783] |
NPT520 | Cell Line | 3T3-L1 | Mus musculus | Activity | = | -1.2 | % | PMID[459785] |
NPT520 | Cell Line | 3T3-L1 | Mus musculus | Activity | = | -3.9 | % | PMID[459785] |
NPT520 | Cell Line | 3T3-L1 | Mus musculus | Activity | = | -14.2 | % | PMID[459785] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | MIC | = | 2.0 | ug.mL-1 | PMID[459787] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | FC | = | 2.0 | n.a. | PMID[459788] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | MIC | > | 100.0 | ug.mL-1 | PMID[459789] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | MEC | = | 25.0 | ug ml-1 | PMID[459789] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | PF | = | 60.0 | n.a. | PMID[459789] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | logPF | = | 1.78 | n.a. | PMID[459789] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | FC | = | 2.0 | n.a. | PMID[459789] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 22.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | -9.0 | % | PMID[459790] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 82.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 2.0 | % | PMID[459790] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 10.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 68.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 46.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 9.0 | % | PMID[459790] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 17.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 23.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | Inhibition | = | 6.0 | % | PMID[459790] |
NPT993 | Cell Line | Hepatocyte | Mus musculus | IC50 | = | 12000.0 | nM | PMID[459790] |
NPT1460 | Cell Line | L929 | Mus musculus | IC50 | = | 42000.0 | nM | PMID[459790] |
NPT1488 | Individual Protein | Monoamine oxidase A | Rattus norvegicus | Ki | = | 49300.0 | nM | PMID[459791] |
NPT1487 | Individual Protein | Monoamine oxidase B | Rattus norvegicus | Ki | = | 91300.0 | nM | PMID[459791] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 5.5 | % | PMID[459792] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 5.3 | % | PMID[459792] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 10.6 | % | PMID[459792] |
NPT1460 | Cell Line | L929 | Mus musculus | Inhibition | = | 41.8 | % | PMID[459792] |
NPT472 | Individual Protein | Vanilloid receptor | Homo sapiens | EC50 | = | 3162.28 | nM | PMID[459794] |
NPT472 | Individual Protein | Vanilloid receptor | Homo sapiens | Emax | = | 91.0 | % | PMID[459794] |
NPT927 | Cell Line | PBMC | Homo sapiens | Activity | = | 7.0 | % | PMID[459795] |
NPT927 | Cell Line | PBMC | Homo sapiens | Activity | = | 10.0 | % | PMID[459795] |
NPT472 | Individual Protein | Vanilloid receptor | Homo sapiens | Activity | = | 10.0 | uM | PMID[459797] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | MEC | = | 50.0 | ug ml-1 | PMID[459798] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | FC | = | 2.0 | n.a. | PMID[459798] |
NPT149 | Individual Protein | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Homo sapiens | Potency | = | 39810.7 | nM | PMID[459799] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 31622.8 | nM | PMID[459799] |
NPT537 | Individual Protein | Ras-related protein Rab-9A | Homo sapiens | Potency | = | 2511.9 | nM | PMID[459800] |
NPT531 | Individual Protein | Nuclear receptor ROR-gamma | Mus musculus | Potency | = | 5623.4 | nM | PMID[459799] |
NPT3 | Individual Protein | Thioredoxin glutathione reductase | Schistosoma mansoni | Potency | = | 39810.7 | nM | PMID[459800] |
NPT282 | Individual Protein | MAP kinase ERK2 | Homo sapiens | Potency | = | 39810.7 | nM | PMID[459799] |
NPT56 | Individual Protein | Beta-lactamase AmpC | Escherichia coli K-12 | Potency | = | 44668.4 | nM | PMID[459800] |
NPT538 | Individual Protein | Niemann-Pick C1 protein | Homo sapiens | Potency | = | 2511.9 | nM | PMID[459800] |
NPT151 | Individual Protein | 15-hydroxyprostaglandin dehydrogenase [NAD+] | Homo sapiens | Potency | = | 15848.9 | nM | PMID[459799] |
NPT109 | Individual Protein | Cytochrome P450 3A4 | Homo sapiens | Potency | = | 12589.3 | nM | PMID[459799] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 20596.2 | nM | PMID[459800] |
NPT64 | Individual Protein | ATPase family AAA domain-containing protein 5 | Homo sapiens | Potency | n.a. | 11577.4 | nM | PMID[459800] |
NPT64 | Individual Protein | ATPase family AAA domain-containing protein 5 | Homo sapiens | Potency | n.a. | 10318.3 | nM | PMID[459800] |
NPT546 | Individual Protein | Retinoid X receptor alpha | Homo sapiens | Potency | n.a. | 35481.3 | nM | PMID[459801] |
NPT540 | Individual Protein | Bile acid receptor FXR | Homo sapiens | Potency | n.a. | 44668.4 | nM | PMID[459801] |
NPT249 | Individual Protein | Glucocorticoid receptor | Homo sapiens | Potency | n.a. | 44668.4 | nM | PMID[459801] |
NPT484 | Individual Protein | Luciferin 4-monooxygenase | Photinus pyralis | Potency | n.a. | 8492.1 | nM | PMID[459800] |
NPT1488 | Individual Protein | Monoamine oxidase A | Rattus norvegicus | IC50 | = | 404.0 | nM | PMID[459802] |
NPT1487 | Individual Protein | Monoamine oxidase B | Rattus norvegicus | IC50 | = | 260.0 | nM | PMID[459802] |
NPT155 | Individual Protein | Aryl hydrocarbon receptor | Homo sapiens | Potency | n.a. | 14125.4 | nM | PMID[459801] |
NPT156 | Individual Protein | Sphingomyelin phosphodiesterase | Homo sapiens | Potency | n.a. | 31622.8 | nM | PMID[459800] |
NPT478 | Individual Protein | Ataxin-2 | Homo sapiens | Potency | n.a. | 19952.6 | nM | PMID[459800] |
NPT157 | Individual Protein | Breast cancer type 1 susceptibility protein | Homo sapiens | Potency | n.a. | 8912.5 | nM | PMID[459800] |
NPT158 | Individual Protein | Nuclear receptor subfamily 1 group I member 2 | Rattus norvegicus | Potency | n.a. | 7079.5 | nM | PMID[459801] |
NPT66 | Individual Protein | Acetylcholinesterase | Electrophorus electricus | Inhibition | = | -0.1 | % | PMID[459804] |
NPT589 | Individual Protein | Serum albumin | Bos taurus | Activity | = | 50.0 | % | PMID[459805] |
NPT582 | Individual Protein | Monoamine oxidase B | Homo sapiens | IC50 | = | 483.0 | nM | PMID[459805] |
NPT261 | Individual Protein | Monoamine oxidase A | Homo sapiens | IC50 | = | 58980.0 | nM | PMID[459805] |
NPT90 | Cell Line | DU-145 | Homo sapiens | IC50 | > | 50000.0 | nM | PMID[459806] |
NPT306 | Cell Line | PC-3 | Homo sapiens | IC50 | > | 50000.0 | nM | PMID[459806] |
NPT1171 | Cell Line | HEp-2 | Homo sapiens | IC50 | = | 70000.0 | nM | PMID[459806] |
NPT407 | Cell Line | COLO 205 | Homo sapiens | IC50 | = | 46000.0 | nM | PMID[459806] |
NPT83 | Cell Line | MCF7 | Homo sapiens | IC50 | = | 99000.0 | nM | PMID[459806] |
NPT744 | Cell Line | IMR-32 | Homo sapiens | IC50 | = | 89000.0 | nM | PMID[459806] |
NPT83 | Cell Line | MCF7 | Homo sapiens | IC50 | = | 990.0 | nM | PMID[459810] |
NPT165 | Cell Line | HeLa | Homo sapiens | IC50 | = | 950.0 | nM | PMID[459810] |
NPT1547 | Individual Protein | Cathepsin D | Homo sapiens | IC50 | = | 42300.0 | nM | PMID[459811] |
NPT82 | Cell Line | MDA-MB-231 | Homo sapiens | IC50 | = | 58.45 | ug.mL-1 | PMID[459811] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 29092.9 | nM | PMID[459800] |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 2433.7 | nM | PMID[459801] |
NPT737 | Cell Line | HUVEC | Homo sapiens | IC50 | = | 100000.0 | nM | PMID[459815] |
NPT737 | Cell Line | HUVEC | Homo sapiens | MTD | = | 250.0 | uM | PMID[459815] |
NPT737 | Cell Line | HUVEC | Homo sapiens | Activity | = | 98.0 | % | PMID[459815] |
NPT113 | Cell Line | RAW264.7 | Mus musculus | Inhibition | = | 49.67 | % | PMID[459818] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | MIC | = | 4.0 | ug.mL-1 | PMID[459819] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | FC | = | 2.0 | n.a. | PMID[459819] |
NPT2795 | Individual Protein | Fluoroquinolone resistance protein | Staphylococcus aureus | MIC | = | 256.0 | ug.mL-1 | PMID[459819] |
NPT2795 | Individual Protein | Fluoroquinolone resistance protein | Staphylococcus aureus | FC | = | 0.0 | n.a. | PMID[459819] |
NPT81 | Cell Line | A549 | Homo sapiens | IC50 | = | 11890.0 | nM | PMID[459824] |
NPT165 | Cell Line | HeLa | Homo sapiens | IC50 | = | 19210.0 | nM | PMID[459824] |
NPT83 | Cell Line | MCF7 | Homo sapiens | IC50 | = | 12960.0 | nM | PMID[459824] |
NPT744 | Cell Line | IMR-32 | Homo sapiens | IC50 | = | 10190.0 | nM | PMID[459824] |
NPT1603 | Individual Protein | Cytochrome P450 1A1 | Homo sapiens | Inhibition | = | 42.0 | % | PMID[459827] |
NPT582 | Individual Protein | Monoamine oxidase B | Homo sapiens | IC50 | = | 1050.0 | nM | PMID[459829] |
NPT261 | Individual Protein | Monoamine oxidase A | Homo sapiens | Inhibition | < | 50.0 | % | PMID[459829] |
NPT570 | Individual Protein | Arachidonate 5-lipoxygenase | Homo sapiens | IC50 | = | 54000.0 | nM | PMID[459831] |
NPT570 | Individual Protein | Arachidonate 5-lipoxygenase | Homo sapiens | Inhibition | = | 47.45 | % | PMID[459832] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | FC | = | 0.0 | n.a. | PMID[459833] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | MEC | > | 50.0 | ug ml-1 | PMID[459833] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | MEC | = | 25.0 | ug ml-1 | PMID[459833] |
NPT2794 | Individual Protein | Quinolone resistance protein norA | Staphylococcus aureus | FC | = | 2.0 | n.a. | PMID[459833] |
NPT65 | Cell Line | HepG2 | Homo sapiens | IC50 | > | 10000.0 | nM | PMID[459839] |
NPT181 | Cell Line | Bel-7402 | Homo sapiens | IC50 | > | 10000.0 | nM | PMID[459839] |
NPT681 | Cell Line | PC-12 | Rattus norvegicus | Activity | = | 55.72 | % | PMID[459840] |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 55068.7 | nM | PubChem BioAssay data set |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 8634.9 | nM | PubChem BioAssay data set |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 2736.2 | nM | PubChem BioAssay data set |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 77115.4 | nM | PubChem BioAssay data set |
NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 15355.3 | nM | PubChem BioAssay data set |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 9708.3 | nM | PubChem BioAssay data set |
NPT106 | Individual Protein | Peroxisome proliferator-activated receptor delta | Homo sapiens | Potency | n.a. | 6932.7 | nM | PubChem BioAssay data set |
NPT317 | Uncleic Acid | Nucleic Acid | Binding | = | 96.6 | pM 30min-1 (mg of DNA)-1 | PMID[459781] | |
NPT317 | Uncleic Acid | Nucleic Acid | Binding | = | 70.0 | pM 30min-1 (mg of DNA)-1 | PMID[459781] | |
NPT317 | Uncleic Acid | Nucleic Acid | Binding | = | 56.6 | pM 30min-1 (mg of DNA)-1 | PMID[459781] | |
NPT317 | Uncleic Acid | Nucleic Acid | Inhibition | = | 27.0 | % | PMID[459781] | |
NPT317 | Uncleic Acid | Nucleic Acid | Inhibition | = | 47.0 | % | PMID[459781] | |
NPT317 | Uncleic Acid | Nucleic Acid | Inhibition | = | 57.0 | % | PMID[459781] | |
NPT580 | Organism | Trypanosoma cruzi | Trypanosoma cruzi | IC50 | = | 7360.0 | nM | PMID[459782] |
NPT580 | Organism | Trypanosoma cruzi | Trypanosoma cruzi | IC50 | = | 4910.0 | nM | PMID[459782] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 0.3 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 50.7 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 96.1 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 23.2 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 51.1 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 94.3 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 15.7 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 9.2 | % | PMID[459783] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | -2.2 | % | PMID[459783] |
NPT580 | Organism | Trypanosoma cruzi | Trypanosoma cruzi | IC50 | = | 7310.0 | nM | PMID[459784] |
NPT580 | Organism | Trypanosoma cruzi | Trypanosoma cruzi | IC50 | = | 4910.0 | nM | PMID[459784] |
NPT27 | Others | Unspecified | LD50 | = | 20.01 | uM | PMID[459784] | |
NPT991 | Individual Protein | Trypanothione reductase | Trypanosoma cruzi | Inhibition | = | 11.0 | % | PMID[459786] |
NPT2 | Others | Unspecified | Inhibition | = | 2.0 | % | PMID[459790] | |
NPT2 | Others | Unspecified | Inhibition | = | 49.0 | % | PMID[459790] | |
NPT2 | Others | Unspecified | Inhibition | = | 11.0 | % | PMID[459790] | |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | -2.2 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 0.3 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 9.2 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 15.7 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 23.2 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 50.7 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 51.1 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 94.3 | % | PMID[459790] |
NPT32 | Organism | Mus musculus | Mus musculus | Inhibition | = | 96.1 | % | PMID[459790] |
NPT892 | Individual Protein | Monoamine oxidase A | Mus musculus | Ki | = | 19000.0 | nM | PMID[459791] |
NPT893 | Individual Protein | Monoamine oxidase B | Mus musculus | Ki | = | 3190.0 | nM | PMID[459791] |
NPT2 | Others | Unspecified | Activity | = | 226.0 | % | PMID[459793] | |
NPT2 | Others | Unspecified | Activity | = | 302.0 | % | PMID[459793] | |
NPT2 | Others | Unspecified | EC50 | = | 52000.0 | nM | PMID[459793] | |
NPT2 | Others | Unspecified | Activity | = | 334.0 | % | PMID[459793] | |
NPT2 | Others | Unspecified | Activity | = | 204.0 | % | PMID[459793] | |
NPT2 | Others | Unspecified | Activity | = | 391.0 | % | PMID[459793] | |
NPT2 | Others | Unspecified | IC50 | = | 1200000.0 | nM | PMID[459793] | |
NPT633 | Organism | Leishmania donovani | Leishmania donovani | IC50 | = | 752000.0 | nM | PMID[459795] |
NPT633 | Organism | Leishmania donovani | Leishmania donovani | IC50 | = | 2558000.0 | nM | PMID[459795] |
NPT580 | Organism | Trypanosoma cruzi | Trypanosoma cruzi | IC50 | = | 5000.0 | nM | PMID[459796] |
NPT2 | Others | Unspecified | Potency | = | 31622.8 | nM | PMID[459799] | |
NPT93 | Individual Protein | Survival motor neuron protein | Homo sapiens | Potency | = | 14125.4 | nM | PMID[459799] |
NPT94 | Individual Protein | Aldehyde dehydrogenase 1A1 | Homo sapiens | Potency | = | 39810.7 | nM | PMID[459799] |
NPT2 | Others | Unspecified | Potency | n.a. | 20596.2 | nM | PMID[459800] | |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 7375.3 | nM | PMID[459800] |
NPT8 | Individual Protein | DNA polymerase iota | Homo sapiens | Potency | n.a. | 89125.1 | nM | PMID[459800] |
NPT2 | Others | Unspecified | Potency | n.a. | 10000.0 | nM | PMID[459800] | |
NPT99 | Individual Protein | Peroxisome proliferator-activated receptor gamma | Homo sapiens | Potency | n.a. | 39810.7 | nM | PMID[459801] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 4653.5 | nM | PMID[459800] |
NPT99 | Individual Protein | Peroxisome proliferator-activated receptor gamma | Homo sapiens | Potency | n.a. | 50118.7 | nM | PMID[459801] |
NPT2 | Others | Unspecified | Ratio IC50 | = | 1.55 | n.a. | PMID[459802] | |
NPT668 | Individual Protein | P-glycoprotein 1 | Homo sapiens | IC50 | = | 15500.0 | nM | PMID[459803] |
NPT668 | Individual Protein | P-glycoprotein 1 | Homo sapiens | IC50 | = | 74100.0 | nM | PMID[459803] |
NPT67 | Individual Protein | Cholinesterase | Equus caballus | Inhibition | = | 16.77 | % | PMID[459804] |
NPT27 | Others | Unspecified | log Pe | = | -3.87 | n.a. | PMID[459805] | |
NPT2564 | Organism | Blumeria graminis | Blumeria graminis | Activity | = | 0.0 | % | PMID[459807] |
NPT829 | Organism | Puccinia recondita | Puccinia recondita | Activity | = | 0.0 | % | PMID[459807] |
NPT825 | Organism | Phytophthora infestans | Phytophthora infestans | Activity | = | 0.0 | % | PMID[459807] |
NPT635 | Organism | Botryotinia fuckeliana | Botryotinia fuckeliana | Activity | = | 0.0 | % | PMID[459807] |
NPT529 | Organism | Rhizoctonia solani | Rhizoctonia solani | Activity | = | 0.0 | % | PMID[459807] |
NPT1198 | Organism | Magnaporthe grisea | Magnaporthe grisea | Activity | = | 0.0 | % | PMID[459807] |
NPT580 | Organism | Trypanosoma cruzi | Trypanosoma cruzi | IC50 | = | 233000.0 | nM | PMID[459808] |
NPT1381 | Organism | Aedes aegypti | Aedes aegypti | LD50 | = | 8.13 | ug | PMID[459809] |
NPT18 | Organism | Pseudomonas aeruginosa | Pseudomonas aeruginosa | MIC | = | 100.0 | ug.mL-1 | PMID[459810] |
NPT16 | Organism | Staphylococcus aureus | Staphylococcus aureus | MIC | = | 300.0 | ug.mL-1 | PMID[459810] |
NPT79 | Organism | Bacillus subtilis | Bacillus subtilis | MIC | = | 500.0 | ug.mL-1 | PMID[459810] |
NPT3152 | Organism | Shigella dysenteriae | Shigella dysenteriae | MIC | = | 600.0 | ug.mL-1 | PMID[459810] |
NPT1242 | Organism | Salmonella typhi | Salmonella enterica subsp. enterica serovar Typhi | MIC | = | 200.0 | ug.mL-1 | PMID[459810] |
NPT173 | Organism | Klebsiella pneumoniae | Klebsiella pneumoniae | MIC | = | 200.0 | ug.mL-1 | PMID[459810] |
NPT19 | Organism | Escherichia coli | Escherichia coli | MIC | = | 300.0 | ug.mL-1 | PMID[459810] |
NPT2 | Others | Unspecified | Ratio CC50/IC50 | = | 16.8 | n.a. | PMID[459813] | |
NPT963 | Organism | Hepatitis B virus | Hepatitis B virus | IC50 | = | 140000.0 | nM | PMID[459813] |
NPT2 | Others | Unspecified | Ratio CC50/IC50 | = | 15.7 | n.a. | PMID[459813] | |
NPT963 | Organism | Hepatitis B virus | Hepatitis B virus | IC50 | = | 150000.0 | nM | PMID[459813] |
NPT27 | Others | Unspecified | CC50 | = | 2350000.0 | nM | PMID[459813] | |
NPT73 | Individual Protein | Solute carrier organic anion transporter family member 1B1 | Homo sapiens | Inhibition | = | 186.17 | % | PMID[459814] |
NPT72 | Individual Protein | Solute carrier organic anion transporter family member 1B3 | Homo sapiens | Inhibition | = | 97.82 | % | PMID[459814] |
NPT610 | Others | Molecular identity unknown | Potency | n.a. | 28183.8 | nM | PMID[459801] | |
NPT2 | Others | Unspecified | Potency | n.a. | 3162.3 | nM | PMID[459799] | |
NPT1007 | Protein Complex | GABA-A receptor; alpha-1/beta-2/gamma-2 | Homo sapiens | Imax | = | 302.0 | % | PMID[459816] |
NPT1007 | Protein Complex | GABA-A receptor; alpha-1/beta-2/gamma-2 | Homo sapiens | EC50 | = | 52400.0 | nM | PMID[459816] |
NPT35 | Others | n.a. | -log(solubility) | = | 4.15 | n.a. | PMID[459817] | |
NPT35 | Others | n.a. | -log(solubility) | = | 4.55 | n.a. | PMID[459817] | |
NPT35 | Others | n.a. | -log(solubility) | = | 4.36 | n.a. | PMID[459817] | |
NPT35 | Others | n.a. | -log(solubility) | = | 4.85 | n.a. | PMID[459817] | |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 0.676 | ml | PMID[459818] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Activity | = | 0.67 | ml | PMID[459818] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 53.69 | % | PMID[459818] |
NPT29 | Organism | Rattus norvegicus | Rattus norvegicus | Inhibition | = | 54.72 | % | PMID[459818] |
NPT2 | Others | Unspecified | Potency | n.a. | 5623.4 | nM | PMID[459799] | |
NPT2 | Others | Unspecified | Potency | n.a. | 3162.3 | nM | PMID[459800] | |
NPT2 | Others | Unspecified | MIC | = | 32.0 | ug.mL-1 | PMID[459819] | |
NPT2 | Others | Unspecified | FC | = | 0.0 | n.a. | PMID[459819] | |
NPT2 | Others | Unspecified | MIC | = | 64.0 | ug.mL-1 | PMID[459819] | |
NPT634 | Organism | Leishmania amazonensis | Leishmania amazonensis | IC50 | = | 14500.0 | nM | PMID[459820] |
NPT605 | Organism | Homo sapiens | Homo sapiens | Cmax | = | 0.4 | ug.mL-1 | PMID[459821] |
NPT605 | Organism | Homo sapiens | Homo sapiens | Tmax | = | 2.5 | hr | PMID[459821] |
NPT605 | Organism | Homo sapiens | Homo sapiens | AUC | = | 3370.0 | ng.hr.mL-1 | PMID[459821] |
NPT605 | Organism | Homo sapiens | Homo sapiens | AUC | = | 5300.0 | ng.hr.mL-1 | PMID[459821] |
NPT605 | Organism | Homo sapiens | Homo sapiens | ka | = | 1.41 | /hr | PMID[459821] |
NPT3664 | Tissue | Serum | Mus musculus | Tmax | = | 6.0 | hr | PMID[459821] |
NPT3664 | Tissue | Serum | Mus musculus | Cmax | = | 5.47 | ug.mL-1 | PMID[459821] |
NPT605 | Organism | Homo sapiens | Homo sapiens | Kel | = | 0.08 | /hr | PMID[459821] |
NPT2 | Others | Unspecified | Inhibition | = | 86.6 | % | PMID[459822] | |
NPT2 | Others | Unspecified | Inhibition | = | 85.1 | % | PMID[459822] | |
NPT2 | Others | Unspecified | Inhibition | = | 67.5 | % | PMID[459822] | |
NPT2 | Others | Unspecified | Inhibition | = | 67.3 | % | PMID[459822] | |
NPT2 | Others | Unspecified | Inhibition | = | 90.2 | % | PMID[459822] | |
NPT2 | Others | Unspecified | Inhibition | = | 75.0 | % | PMID[459822] | |
NPT2 | Others | Unspecified | Inhibition | = | 90.0 | % | PMID[459822] | |
NPT617 | Organism | Danio rerio | Danio rerio | MTD | = | 12.0 | uM | PMID[459823] |
NPT16 | Organism | Staphylococcus aureus | Staphylococcus aureus | MIC | = | 119000.0 | nM | PMID[459825] |
NPT16 | Organism | Staphylococcus aureus | Staphylococcus aureus | IC50 | = | 72300.0 | nM | PMID[459825] |
NPT2 | Others | Unspecified | FC | = | 32.0 | n.a. | PMID[459826] | |
NPT2 | Others | Unspecified | FC | = | 14.0 | n.a. | PMID[459826] | |
NPT2 | Others | Unspecified | FC | = | 7.0 | n.a. | PMID[459826] | |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | -5.85 | % | PMID[459828] |
NPT2 | Others | Unspecified | Ratio IC50 | = | 10.0 | n.a. | PMID[459829] | |
NPT35 | Others | n.a. | Retention_time | = | 10.61 | min | PMID[459829] | |
NPT35 | Others | n.a. | CHI | = | 73.45 | n.a. | PMID[459829] | |
NPT35 | Others | n.a. | LogD | = | 2.39 | n.a. | PMID[459829] | |
NPT20 | Organism | Candida albicans | Candida albicans | MIC | = | 3125.0 | ug.mL-1 | PMID[459830] |
NPT18 | Organism | Pseudomonas aeruginosa | Pseudomonas aeruginosa | MIC | = | 100000.0 | ug.mL-1 | PMID[459830] |
NPT766 | Organism | Proteus vulgaris | Proteus vulgaris | MIC | = | 12500.0 | ug.mL-1 | PMID[459830] |
NPT173 | Organism | Klebsiella pneumoniae | Klebsiella pneumoniae | MIC | = | 25000.0 | ug.mL-1 | PMID[459830] |
NPT16 | Organism | Staphylococcus aureus | Staphylococcus aureus | MIC | = | 50000.0 | ug.mL-1 | PMID[459830] |
NPT19 | Organism | Escherichia coli | Escherichia coli | MIC | = | 6250.0 | ug.mL-1 | PMID[459830] |
NPT20 | Organism | Candida albicans | Candida albicans | IZ | = | 23.0 | mm | PMID[459830] |
NPT18 | Organism | Pseudomonas aeruginosa | Pseudomonas aeruginosa | IZ | = | 8.0 | mm | PMID[459830] |
NPT766 | Organism | Proteus vulgaris | Proteus vulgaris | IZ | = | 17.0 | mm | PMID[459830] |
NPT173 | Organism | Klebsiella pneumoniae | Klebsiella pneumoniae | IZ | = | 15.0 | mm | PMID[459830] |
NPT16 | Organism | Staphylococcus aureus | Staphylococcus aureus | IZ | = | 12.0 | mm | PMID[459830] |
NPT19 | Organism | Escherichia coli | Escherichia coli | IZ | = | 20.0 | mm | PMID[459830] |
NPT16 | Organism | Staphylococcus aureus | Staphylococcus aureus | MIC | > | 50.0 | ug.mL-1 | PMID[459833] |
NPT20556 | SINGLE PROTEIN | Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | 16.44 | % | PMID[459834] |
NPT20556 | SINGLE PROTEIN | Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | 22.14 | % | PMID[459835] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | -0.04 | % | PMID[459836] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | Inhibition | = | 0.22 | % | PMID[459837] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | IC50 | > | 20000.0 | nM | PMID[459838] |
NPT20555 | ORGANISM | SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 | IC50 | > | 19952.62 | nM | PMID[459838] |
NPT2 | Others | Unspecified | Potency | n.a. | 3857.1 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 1371.3 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 55068.7 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 68729.1 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 1737.6 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 38649.2 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 43742.7 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 1368.5 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 61652.4 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 54482.7 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 612.5 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 865.2 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 2169 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 38900 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 61254.9 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 61130.6 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 13685.4 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 771.2 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 54947.7 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 1933.1 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 10892.8 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 6932.7 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 9771.2 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 3864.9 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 3063.8 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | n.a. | 8652.5 | nM | PubChem BioAssay data set |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC136330 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC230698 |
1.0 | High Similarity | NPC73883 |
1.0 | High Similarity | NPC196609 |
1.0 | High Similarity | NPC277042 |
1.0 | High Similarity | NPC255817 |
1.0 | High Similarity | NPC205178 |
1.0 | High Similarity | NPC251454 |
0.9922 | High Similarity | NPC99078 |
0.9921 | High Similarity | NPC167096 |
0.9845 | High Similarity | NPC252107 |
0.9845 | High Similarity | NPC220923 |
0.9845 | High Similarity | NPC470707 |
0.9462 | High Similarity | NPC103947 |
0.9462 | High Similarity | NPC94280 |
0.9462 | High Similarity | NPC45783 |
0.9462 | High Similarity | NPC159150 |
0.9462 | High Similarity | NPC193673 |
0.9462 | High Similarity | NPC328419 |
0.9389 | High Similarity | NPC96406 |
0.9389 | High Similarity | NPC180647 |
0.9318 | High Similarity | NPC145446 |
0.9318 | High Similarity | NPC137172 |
0.9308 | High Similarity | NPC217574 |
0.9248 | High Similarity | NPC225745 |
0.9248 | High Similarity | NPC248505 |
0.9248 | High Similarity | NPC95366 |
0.9173 | High Similarity | NPC469808 |
0.9015 | High Similarity | NPC318862 |
0.8881 | High Similarity | NPC471073 |
0.8881 | High Similarity | NPC270811 |
0.8824 | High Similarity | NPC194359 |
0.8824 | High Similarity | NPC28641 |
0.8759 | High Similarity | NPC231572 |
0.8714 | High Similarity | NPC244338 |
0.8521 | High Similarity | NPC469978 |
0.8503 | High Similarity | NPC169742 |
0.8345 | Intermediate Similarity | NPC416184 |
0.8311 | Intermediate Similarity | NPC470708 |
0.8288 | Intermediate Similarity | NPC470088 |
0.8286 | Intermediate Similarity | NPC113236 |
0.8286 | Intermediate Similarity | NPC214036 |
0.8235 | Intermediate Similarity | NPC231198 |
0.8214 | Intermediate Similarity | NPC7018 |
0.8168 | Intermediate Similarity | NPC69670 |
0.8108 | Intermediate Similarity | NPC223125 |
0.8077 | Intermediate Similarity | NPC111225 |
0.806 | Intermediate Similarity | NPC256167 |
0.8043 | Intermediate Similarity | NPC470706 |
0.8015 | Intermediate Similarity | NPC199209 |
0.8015 | Intermediate Similarity | NPC212643 |
0.8 | Intermediate Similarity | NPC223124 |
0.7985 | Intermediate Similarity | NPC114845 |
0.7974 | Intermediate Similarity | NPC106786 |
0.7973 | Intermediate Similarity | NPC475959 |
0.7956 | Intermediate Similarity | NPC251466 |
0.7956 | Intermediate Similarity | NPC218323 |
0.7935 | Intermediate Similarity | NPC59567 |
0.7929 | Intermediate Similarity | NPC118419 |
0.7899 | Intermediate Similarity | NPC172403 |
0.7895 | Intermediate Similarity | NPC57501 |
0.7883 | Intermediate Similarity | NPC170583 |
0.7883 | Intermediate Similarity | NPC71105 |
0.7883 | Intermediate Similarity | NPC152186 |
0.7883 | Intermediate Similarity | NPC182147 |
0.7883 | Intermediate Similarity | NPC207541 |
0.7883 | Intermediate Similarity | NPC246133 |
0.7848 | Intermediate Similarity | NPC241055 |
0.7842 | Intermediate Similarity | NPC469977 |
0.7826 | Intermediate Similarity | NPC156944 |
0.7817 | Intermediate Similarity | NPC473463 |
0.7812 | Intermediate Similarity | NPC127326 |
0.781 | Intermediate Similarity | NPC300955 |
0.7786 | Intermediate Similarity | NPC160193 |
0.777 | Intermediate Similarity | NPC157740 |
0.777 | Intermediate Similarity | NPC191302 |
0.777 | Intermediate Similarity | NPC64948 |
0.777 | Intermediate Similarity | NPC41331 |
0.777 | Intermediate Similarity | NPC291449 |
0.777 | Intermediate Similarity | NPC99798 |
0.7763 | Intermediate Similarity | NPC148898 |
0.7762 | Intermediate Similarity | NPC11147 |
0.7752 | Intermediate Similarity | NPC31279 |
0.7721 | Intermediate Similarity | NPC193484 |
0.7714 | Intermediate Similarity | NPC147247 |
0.7714 | Intermediate Similarity | NPC246974 |
0.7697 | Intermediate Similarity | NPC119669 |
0.7692 | Intermediate Similarity | NPC284855 |
0.7692 | Intermediate Similarity | NPC282477 |
0.7662 | Intermediate Similarity | NPC41178 |
0.7662 | Intermediate Similarity | NPC76079 |
0.7662 | Intermediate Similarity | NPC138487 |
0.7662 | Intermediate Similarity | NPC78733 |
0.7662 | Intermediate Similarity | NPC93593 |
0.7662 | Intermediate Similarity | NPC216459 |
0.7658 | Intermediate Similarity | NPC306669 |
0.7658 | Intermediate Similarity | NPC168409 |
0.7655 | Intermediate Similarity | NPC193528 |
0.7651 | Intermediate Similarity | NPC145304 |
0.7647 | Intermediate Similarity | NPC233029 |
0.7647 | Intermediate Similarity | NPC210148 |
0.7626 | Intermediate Similarity | NPC85830 |
0.7622 | Intermediate Similarity | NPC266425 |
0.7616 | Intermediate Similarity | NPC37144 |
0.7616 | Intermediate Similarity | NPC59907 |
0.7613 | Intermediate Similarity | NPC31311 |
0.7613 | Intermediate Similarity | NPC234392 |
0.7613 | Intermediate Similarity | NPC146288 |
0.7605 | Intermediate Similarity | NPC471650 |
0.759 | Intermediate Similarity | NPC116007 |
0.7582 | Intermediate Similarity | NPC476579 |
0.7582 | Intermediate Similarity | NPC474852 |
0.7574 | Intermediate Similarity | NPC344161 |
0.7556 | Intermediate Similarity | NPC277460 |
0.7551 | Intermediate Similarity | NPC314682 |
0.7537 | Intermediate Similarity | NPC268317 |
0.7536 | Intermediate Similarity | NPC298486 |
0.7534 | Intermediate Similarity | NPC254610 |
0.7517 | Intermediate Similarity | NPC475828 |
0.7516 | Intermediate Similarity | NPC329640 |
0.75 | Intermediate Similarity | NPC213206 |
0.75 | Intermediate Similarity | NPC477259 |
0.75 | Intermediate Similarity | NPC169387 |
0.75 | Intermediate Similarity | NPC328750 |
0.75 | Intermediate Similarity | NPC474915 |
0.75 | Intermediate Similarity | NPC188163 |
0.7485 | Intermediate Similarity | NPC83511 |
0.7485 | Intermediate Similarity | NPC4669 |
0.7483 | Intermediate Similarity | NPC477694 |
0.7483 | Intermediate Similarity | NPC477705 |
0.7481 | Intermediate Similarity | NPC280001 |
0.7481 | Intermediate Similarity | NPC185738 |
0.7481 | Intermediate Similarity | NPC179309 |
0.7468 | Intermediate Similarity | NPC215829 |
0.7468 | Intermediate Similarity | NPC306902 |
0.7468 | Intermediate Similarity | NPC85747 |
0.7468 | Intermediate Similarity | NPC97072 |
0.7468 | Intermediate Similarity | NPC8337 |
0.7468 | Intermediate Similarity | NPC160298 |
0.7468 | Intermediate Similarity | NPC266753 |
0.7468 | Intermediate Similarity | NPC477559 |
0.7468 | Intermediate Similarity | NPC232924 |
0.7464 | Intermediate Similarity | NPC80241 |
0.7464 | Intermediate Similarity | NPC301641 |
0.7451 | Intermediate Similarity | NPC211296 |
0.7434 | Intermediate Similarity | NPC95075 |
0.7434 | Intermediate Similarity | NPC253883 |
0.7434 | Intermediate Similarity | NPC90844 |
0.7431 | Intermediate Similarity | NPC477706 |
0.7425 | Intermediate Similarity | NPC102760 |
0.7423 | Intermediate Similarity | NPC303581 |
0.7423 | Intermediate Similarity | NPC67978 |
0.7419 | Intermediate Similarity | NPC476580 |
0.7417 | Intermediate Similarity | NPC130926 |
0.7407 | Intermediate Similarity | NPC86469 |
0.7405 | Intermediate Similarity | NPC118804 |
0.7405 | Intermediate Similarity | NPC477080 |
0.7405 | Intermediate Similarity | NPC111485 |
0.7394 | Intermediate Similarity | NPC286683 |
0.7391 | Intermediate Similarity | NPC471877 |
0.7388 | Intermediate Similarity | NPC294941 |
0.7379 | Intermediate Similarity | NPC160692 |
0.7376 | Intermediate Similarity | NPC120066 |
0.7358 | Intermediate Similarity | NPC135006 |
0.7358 | Intermediate Similarity | NPC26353 |
0.7357 | Intermediate Similarity | NPC249788 |
0.7353 | Intermediate Similarity | NPC120075 |
0.7353 | Intermediate Similarity | NPC33271 |
0.7347 | Intermediate Similarity | NPC42793 |
0.7347 | Intermediate Similarity | NPC301050 |
0.7347 | Intermediate Similarity | NPC307682 |
0.7347 | Intermediate Similarity | NPC231884 |
0.7347 | Intermediate Similarity | NPC167944 |
0.7347 | Intermediate Similarity | NPC131204 |
0.7346 | Intermediate Similarity | NPC474324 |
0.7346 | Intermediate Similarity | NPC57812 |
0.7338 | Intermediate Similarity | NPC469540 |
0.7338 | Intermediate Similarity | NPC219162 |
0.7338 | Intermediate Similarity | NPC469539 |
0.7333 | Intermediate Similarity | NPC181905 |
0.7333 | Intermediate Similarity | NPC308267 |
0.7333 | Intermediate Similarity | NPC138438 |
0.7333 | Intermediate Similarity | NPC908 |
0.7329 | Intermediate Similarity | NPC232514 |
0.7329 | Intermediate Similarity | NPC276944 |
0.7329 | Intermediate Similarity | NPC238530 |
0.7329 | Intermediate Similarity | NPC35345 |
0.7329 | Intermediate Similarity | NPC225774 |
0.7324 | Intermediate Similarity | NPC301713 |
0.7315 | Intermediate Similarity | NPC226005 |
0.7305 | Intermediate Similarity | NPC27887 |
0.7303 | Intermediate Similarity | NPC185838 |
0.7301 | Intermediate Similarity | NPC475845 |
0.7297 | Intermediate Similarity | NPC253429 |
0.7297 | Intermediate Similarity | NPC230968 |
0.7297 | Intermediate Similarity | NPC102260 |
0.7292 | Intermediate Similarity | NPC200555 |
0.7292 | Intermediate Similarity | NPC476748 |
0.7292 | Intermediate Similarity | NPC196026 |
0.7285 | Intermediate Similarity | NPC136860 |
0.7285 | Intermediate Similarity | NPC128019 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC136330 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
1.0 | High Similarity | NPD2492 | Phase 1 |
0.8462 | Intermediate Similarity | NPD5297 | Approved |
0.8014 | Intermediate Similarity | NPD6783 | Clinical (unspecified phase) |
0.7881 | Intermediate Similarity | NPD1337 | Clinical (unspecified phase) |
0.7857 | Intermediate Similarity | NPD5718 | Phase 2 |
0.7823 | Intermediate Similarity | NPD5084 | Clinical (unspecified phase) |
0.7801 | Intermediate Similarity | NPD554 | Clinical (unspecified phase) |
0.7714 | Intermediate Similarity | NPD5752 | Clinical (unspecified phase) |
0.7654 | Intermediate Similarity | NPD3885 | Approved |
0.7582 | Intermediate Similarity | NPD824 | Approved |
0.7535 | Intermediate Similarity | NPD2669 | Clinical (unspecified phase) |
0.7534 | Intermediate Similarity | NPD6029 | Clinical (unspecified phase) |
0.7534 | Intermediate Similarity | NPD6028 | Clinical (unspecified phase) |
0.75 | Intermediate Similarity | NPD4664 | Clinical (unspecified phase) |
0.7484 | Intermediate Similarity | NPD7109 | Clinical (unspecified phase) |
0.7484 | Intermediate Similarity | NPD7110 | Phase 1 |
0.7481 | Intermediate Similarity | NPD5536 | Phase 2 |
0.7468 | Intermediate Similarity | NPD5604 | Discontinued |
0.7452 | Intermediate Similarity | NPD5977 | Approved |
0.7452 | Intermediate Similarity | NPD5978 | Approved |
0.7451 | Intermediate Similarity | NPD6662 | Clinical (unspecified phase) |
0.7445 | Intermediate Similarity | NPD2423 | Clinical (unspecified phase) |
0.7403 | Intermediate Similarity | NPD4210 | Discontinued |
0.7372 | Intermediate Similarity | NPD1357 | Approved |
0.7347 | Intermediate Similarity | NPD6895 | Approved |
0.7347 | Intermediate Similarity | NPD6896 | Approved |
0.7347 | Intermediate Similarity | NPD743 | Approved |
0.7333 | Intermediate Similarity | NPD4237 | Approved |
0.7333 | Intermediate Similarity | NPD4236 | Phase 3 |
0.7325 | Intermediate Similarity | NPD7945 | Clinical (unspecified phase) |
0.7284 | Intermediate Similarity | NPD4166 | Phase 2 |
0.7279 | Intermediate Similarity | NPD2653 | Approved |
0.7262 | Intermediate Similarity | NPD7280 | Phase 3 |
0.7262 | Intermediate Similarity | NPD7281 | Phase 3 |
0.7261 | Intermediate Similarity | NPD6873 | Phase 2 |
0.7261 | Intermediate Similarity | NPD6385 | Approved |
0.7261 | Intermediate Similarity | NPD6386 | Approved |
0.726 | Intermediate Similarity | NPD3142 | Approved |
0.726 | Intermediate Similarity | NPD3140 | Approved |
0.7234 | Intermediate Similarity | NPD1420 | Approved |
0.7234 | Intermediate Similarity | NPD1421 | Approved |
0.7226 | Intermediate Similarity | NPD3640 | Phase 3 |
0.7226 | Intermediate Similarity | NPD3641 | Approved |
0.7226 | Intermediate Similarity | NPD3639 | Approved |
0.7214 | Intermediate Similarity | NPD3705 | Approved |
0.7208 | Intermediate Similarity | NPD3146 | Approved |
0.7208 | Intermediate Similarity | NPD3688 | Clinical (unspecified phase) |
0.7208 | Intermediate Similarity | NPD4584 | Approved |
0.72 | Intermediate Similarity | NPD3656 | Approved |
0.7197 | Intermediate Similarity | NPD6875 | Approved |
0.7197 | Intermediate Similarity | NPD6876 | Approved |
0.7175 | Intermediate Similarity | NPD5457 | Discontinued |
0.717 | Intermediate Similarity | NPD2978 | Approved |
0.717 | Intermediate Similarity | NPD2977 | Approved |
0.7143 | Intermediate Similarity | NPD4357 | Discontinued |
0.7124 | Intermediate Similarity | NPD2219 | Phase 1 |
0.7123 | Intermediate Similarity | NPD3144 | Approved |
0.7123 | Intermediate Similarity | NPD3145 | Approved |
0.7122 | Intermediate Similarity | NPD6382 | Discontinued |
0.7114 | Intermediate Similarity | NPD6111 | Discontinued |
0.7113 | Intermediate Similarity | NPD4379 | Clinical (unspecified phase) |
0.7105 | Intermediate Similarity | NPD5177 | Phase 3 |
0.7097 | Intermediate Similarity | NPD1424 | Approved |
0.7091 | Intermediate Similarity | NPD2898 | Approved |
0.7075 | Intermediate Similarity | NPD3531 | Approved |
0.7075 | Intermediate Similarity | NPD3532 | Approved |
0.7075 | Intermediate Similarity | NPD3530 | Approved |
0.7075 | Intermediate Similarity | NPD2674 | Phase 3 |
0.7075 | Intermediate Similarity | NPD2245 | Discovery |
0.7071 | Intermediate Similarity | NPD2668 | Approved |
0.7071 | Intermediate Similarity | NPD2667 | Approved |
0.7063 | Intermediate Similarity | NPD7258 | Clinical (unspecified phase) |
0.7059 | Intermediate Similarity | NPD5481 | Discontinued |
0.7059 | Intermediate Similarity | NPD5283 | Phase 1 |
0.7047 | Intermediate Similarity | NPD4579 | Clinical (unspecified phase) |
0.7025 | Intermediate Similarity | NPD4017 | Approved |
0.7021 | Intermediate Similarity | NPD3447 | Discontinued |
0.702 | Intermediate Similarity | NPD1725 | Approved |
0.7019 | Intermediate Similarity | NPD5353 | Approved |
0.7018 | Intermediate Similarity | NPD6618 | Phase 2 |
0.7013 | Intermediate Similarity | NPD5241 | Discontinued |
0.7006 | Intermediate Similarity | NPD6030 | Approved |
0.7006 | Intermediate Similarity | NPD1670 | Discontinued |
0.7006 | Intermediate Similarity | NPD6031 | Approved |
0.7006 | Intermediate Similarity | NPD2122 | Discontinued |
0.6994 | Remote Similarity | NPD3349 | Phase 2 |
0.6993 | Remote Similarity | NPD4162 | Approved |
0.6993 | Remote Similarity | NPD3060 | Approved |
0.6992 | Remote Similarity | NPD1358 | Approved |
0.6989 | Remote Similarity | NPD6493 | Phase 3 |
0.6982 | Remote Similarity | NPD6297 | Approved |
0.6978 | Remote Similarity | NPD7607 | Clinical (unspecified phase) |
0.6974 | Remote Similarity | NPD1375 | Discontinued |
0.6968 | Remote Similarity | NPD5295 | Discontinued |
0.6968 | Remote Similarity | NPD7124 | Phase 2 |
0.6964 | Remote Similarity | NPD5312 | Approved |
0.6964 | Remote Similarity | NPD5313 | Approved |
0.6962 | Remote Similarity | NPD4124 | Clinical (unspecified phase) |
0.6951 | Remote Similarity | NPD5677 | Discontinued |
0.6944 | Remote Similarity | NPD2922 | Phase 1 |
0.6928 | Remote Similarity | NPD1372 | Clinical (unspecified phase) |
0.6928 | Remote Similarity | NPD1044 | Clinical (unspecified phase) |
0.6923 | Remote Similarity | NPD2233 | Approved |
0.6923 | Remote Similarity | NPD2232 | Approved |
0.6923 | Remote Similarity | NPD2230 | Approved |
0.6918 | Remote Similarity | NPD2040 | Clinical (unspecified phase) |
0.6917 | Remote Similarity | NPD3134 | Approved |
0.6913 | Remote Similarity | NPD3110 | Approved |
0.6913 | Remote Similarity | NPD3109 | Approved |
0.6903 | Remote Similarity | NPD5307 | Clinical (unspecified phase) |
0.6899 | Remote Similarity | NPD4727 | Phase 1 |
0.6897 | Remote Similarity | NPD7291 | Discontinued |
0.6894 | Remote Similarity | NPD3384 | Approved |
0.6894 | Remote Similarity | NPD3383 | Approved |
0.6894 | Remote Similarity | NPD3382 | Approved |
0.6892 | Remote Similarity | NPD3374 | Clinical (unspecified phase) |
0.6887 | Remote Similarity | NPD7119 | Phase 2 |
0.6886 | Remote Similarity | NPD4481 | Phase 3 |
0.6879 | Remote Similarity | NPD2595 | Approved |
0.6879 | Remote Similarity | NPD4739 | Approved |
0.6879 | Remote Similarity | NPD2594 | Approved |
0.6859 | Remote Similarity | NPD160 | Clinical (unspecified phase) |
0.6859 | Remote Similarity | NPD2120 | Phase 2 |
0.6854 | Remote Similarity | NPD5582 | Discontinued |
0.6852 | Remote Similarity | NPD6818 | Clinical (unspecified phase) |
0.6852 | Remote Similarity | NPD5772 | Approved |
0.6852 | Remote Similarity | NPD5773 | Approved |
0.6852 | Remote Similarity | NPD5563 | Clinical (unspecified phase) |
0.6849 | Remote Similarity | NPD7905 | Discontinued |
0.6835 | Remote Similarity | NPD3647 | Clinical (unspecified phase) |
0.6832 | Remote Similarity | NPD4773 | Phase 2 |
0.6832 | Remote Similarity | NPD4772 | Phase 2 |
0.6824 | Remote Similarity | NPD5746 | Approved |
0.6821 | Remote Similarity | NPD6853 | Approved |
0.6821 | Remote Similarity | NPD6851 | Approved |
0.6818 | Remote Similarity | NPD5525 | Clinical (unspecified phase) |
0.6815 | Remote Similarity | NPD6143 | Clinical (unspecified phase) |
0.6813 | Remote Similarity | NPD7261 | Clinical (unspecified phase) |
0.681 | Remote Similarity | NPD2560 | Approved |
0.681 | Remote Similarity | NPD2563 | Approved |
0.6807 | Remote Similarity | NPD6107 | Approved |
0.6802 | Remote Similarity | NPD7132 | Clinical (unspecified phase) |
0.6797 | Remote Similarity | NPD2161 | Phase 2 |
0.6792 | Remote Similarity | NPD6980 | Clinical (unspecified phase) |
0.6792 | Remote Similarity | NPD5976 | Discontinued |
0.679 | Remote Similarity | NPD7298 | Approved |
0.6788 | Remote Similarity | NPD228 | Approved |
0.6786 | Remote Similarity | NPD3596 | Phase 2 |
0.6781 | Remote Similarity | NPD4098 | Discontinued |
0.6779 | Remote Similarity | NPD1336 | Approved |
0.6778 | Remote Similarity | NPD4420 | Approved |
0.6772 | Remote Similarity | NPD2335 | Discontinued |
0.6772 | Remote Similarity | NPD1754 | Clinical (unspecified phase) |
0.6772 | Remote Similarity | NPD4123 | Phase 3 |
0.677 | Remote Similarity | NPD2592 | Discontinued |
0.6768 | Remote Similarity | NPD6788 | Approved |
0.6768 | Remote Similarity | NPD5019 | Clinical (unspecified phase) |
0.6766 | Remote Similarity | NPD6071 | Discontinued |
0.675 | Remote Similarity | NPD3687 | Approved |
0.675 | Remote Similarity | NPD3686 | Approved |
0.6748 | Remote Similarity | NPD4585 | Approved |
0.6747 | Remote Similarity | NPD2042 | Clinical (unspecified phase) |
0.6747 | Remote Similarity | NPD2041 | Clinical (unspecified phase) |
0.6735 | Remote Similarity | NPD7018 | Phase 2 |
0.6733 | Remote Similarity | NPD5745 | Approved |
0.6732 | Remote Similarity | NPD3693 | Clinical (unspecified phase) |
0.6732 | Remote Similarity | NPD4108 | Discontinued |
0.6731 | Remote Similarity | NPD5754 | Discontinued |
0.6731 | Remote Similarity | NPD6331 | Phase 2 |
0.673 | Remote Similarity | NPD1975 | Clinical (unspecified phase) |
0.6727 | Remote Similarity | NPD1309 | Phase 2 |
0.6727 | Remote Similarity | NPD1307 | Phase 2 |
0.6726 | Remote Similarity | NPD5242 | Approved |
0.6726 | Remote Similarity | NPD2388 | Discontinued |
0.6711 | Remote Similarity | NPD5163 | Phase 2 |
0.671 | Remote Similarity | NPD7153 | Discontinued |
0.6708 | Remote Similarity | NPD3866 | Clinical (unspecified phase) |
0.6707 | Remote Similarity | NPD5967 | Approved |
0.6706 | Remote Similarity | NPD2822 | Clinical (unspecified phase) |
0.6705 | Remote Similarity | NPD7549 | Discontinued |
0.669 | Remote Similarity | NPD2486 | Discontinued |
0.6688 | Remote Similarity | NPD3156 | Discontinued |
0.6667 | Remote Similarity | NPD3051 | Approved |
0.6667 | Remote Similarity | NPD7235 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD1039 | Discontinued |
0.6667 | Remote Similarity | NPD6377 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD6812 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD3294 | Phase 2 |
0.6648 | Remote Similarity | NPD4084 | Clinical (unspecified phase) |
0.6647 | Remote Similarity | NPD2904 | Discontinued |
0.6647 | Remote Similarity | NPD5966 | Clinical (unspecified phase) |
0.6647 | Remote Similarity | NPD7201 | Clinical (unspecified phase) |
0.6646 | Remote Similarity | NPD3281 | Clinical (unspecified phase) |
0.6645 | Remote Similarity | NPD5865 | Clinical (unspecified phase) |
0.6644 | Remote Similarity | NPD1669 | Approved |
0.663 | Remote Similarity | NPD5006 | Approved |
0.663 | Remote Similarity | NPD5564 | Approved |
0.663 | Remote Similarity | NPD5005 | Approved |
0.6629 | Remote Similarity | NPD7090 | Clinical (unspecified phase) |
0.6627 | Remote Similarity | NPD7832 | Clinical (unspecified phase) |
Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.